ClinicalTrials.gg
RecruitingNCT06859762Updated Sep 18, 2026

A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors

A Phase 1 interventional study of YL217 and Bevacizumab in Advanced Solid Tumor, sponsored by MediLink Therapeutics (Suzhou) Co., Ltd.. Recruiting at 21 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-18.

Sponsored by MediLink Therapeutics (Suzhou) Co., Ltd. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
630
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

A Phase 1 First-in-Human study of YL217 in Patients with Advanced Solid Tumors

Read the detailed description

YL217 is an antibody-drug conjugate (ADC) that targets CDH17 (Cadherin-17) protein and is being developed for the treatment of cancer. YL217 is comprised of three components: 1) YL217-mAb, a CDH17-targeting recombinant humanized immunoglobulin G1 (IgG1) monoclonal antibody, 2) YL0010014, a topoisomerase I inhibitor, and 3) an enzymatically cleavable methylsulfonyl pyrimidine tripeptide drug linker.

The in vivo anti-tumor efficacy of YL217 was evaluated in immune-deficient mice bearing human colorectal cancer, gastric cancer and patient derived colorectal cancer xenograft tumors. The results indicated that YL217 was well tolerated, and YL217 suppressed growth of established human tumors in a dose-dependent manner in cancer cells or patient derived xenograft models.

Therefore, in order to meet the huge unmet medical needs in the field of gastrointestinal cancer treatment, it is planned to conduct the first human phase I clinical study of YL217 in patients with advanced solid tumors.

02

Conditions studied

  • Advanced Solid Tumor
03

In context

Lead sponsor

MediLink Therapeutics (Suzhou) Co., Ltd. is the lead sponsor of 23 studies on the registry; 18 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Informed of the study before the start of the study and voluntarily sign their name and date in the ICF
  • Able and willing to comply with protocol visits and procedures
  • Age≥ 18 years
  • PS of 0 or 1
  • confirmed diagnosis of an advanced solid tumor. For CRC cohorts: : Histologically or cytologically documented locally advanced unresectable or colorectal carcinoma that is not eligible for curative surgery and/or definitive chemoradiotherapy
  • Adequate organ and bone marrow function.
  • Have at least 1 extracranial measurable tumor lesion.
  • Adequate archival formalin-fixed paraffin embedded (FFPE) tissue from prior .

Exclusion criteria

Exclusion Criteria:

  • Prior treatment with an agent targeting CDH17
  • Prior discontinuation of a topoisomerase I inhibitor due to treatment-related toxicities.
  • Have received an ADC consisting of a topoisomerase I inhibitor.
  • Concurrent enrollment in another clinical study, unless it is an observational clinical study.
  • Inadequate for prior anticancer treatment before the first dose of study drug
  • Undergone major surgery within 4 weeks before the first dose of study drug or expect major surgery during the study, minor procedures (e.g., core needle , superficial biopsy) within 7 days before the first dose of study drug.
  • Received long term systemic or other therapy within 2 weeks before the first dose of study drug.
  • Received any within 4 weeks before the first dose of study drug or intend to receive a live vaccine during the study.
  • Diagnosis or evidence of spinal cord compression or .
  • Uncontrolled or cardiovascular and cerebrovascular diseases.
  • A history of non-infectious interstitial lung disease (ILD)/pneumonitis that requires steroids, current active ILD/pneumonitis.
  • Have clinically severe pulmonary compromise resulting from intercurrent pulmonary illnesses.
  • Uncontrolled third-space fluid that requires repeated drainage.
  • Digestive system disease that may cause bleeding, perforation, jaundice, fistula, GI obstruction within 6 months prior to the first dose of study drug administration or have active inflammatory bowel disease.
  • An active tuberculosis based on medical history.
  • Known (HIV) infection.
  • Active infection.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
630 participants (estimated)

Study arms

  • Experimental
    Combo-Dose Escalation,Backfill and Expansion

    Participants will receive YL217 in combination of bevacizumab with or without 5-FU/LV

    Drug: YL217 · Drug: Bevacizumab · Drug: 5-FU with leucovorin

  • Experimental
    Mono-Dose Escalation,Backfill and Expansion

    Participants will receive YL217 monotherapy

    Drug: YL217

Interventions

  • DrugYL217

    Patients will receive specific dose of YL217 administered via intravenous(IV)infusion.

  • Participants will receive bevacizumab administered via intravenous(IV) infusion,at 5mg/kg,Q2W.

  • Drug5-FU with leucovorin

    Drug pages: Fluorouracil · Leucovorin

    Participants will receive 5 fluorouracil 2400mg/m2 and leucovorin 400mg/m2, administered via intravenous (IV) infusion, Q2W

06

What researchers measure

Primary outcomes

  1. Nature and frequency of dose-limiting toxicity(DLT)

    The purpose of DLT is to find maximum tolerated dose (MTD).

    Time frame: Up to approximately 3 years

  2. Nature and frequency of adverse events (AEs) with severity

    Nature and frequency of AEs with severity is aim to evaluate the safety of YL217.

    Time frame: Up to approximately 3 years

  3. objective response rate (ORR)

    ORR: defined as the proportion of patients who achieved a best overall response of complete response (CR) or partial response (PR).

    Time frame: Up to approximately 3 years

Secondary outcomes

  1. Eastern Cooperative Oncology Group performance status (ECOG PS)

    Deterioration of Eastern Cooperative Oncology Group performance status (ECOG PS)

    Time frame: Up to approximately 3 years

  2. To evaluate safety endpoint of peripheral oxygen saturation (SpO2)

    Time frame: Up to approximately 3 years

  3. Characterize Pharmacokinetics(PK) parameter AUC

    The area under curve: AUC is the total amount of YL217 in bloodstream after drug administration.

    Time frame: Up to approximately 3 years

  4. Characterize Pharmacokinetics(PK) parameter Cmax

    Maximum concentration:The highest measured concentration of YL217 in the bloodstream.

    Time frame: Up to approximately 3 years

  5. Characterize Pharmacokinetics(PK) parameter Ctrough

    Trough concentration

    Time frame: Up to approximately 3 years

  6. Characterize Pharmacokinetics(PK) parameter Tmax

    Time to maximum observed concentration

    Time frame: Up to approximately 3 years

  7. Characterize Pharmacokinetics(PK) parameter CL

    Clearance: defined as the amount of drug removed from the bloodstream by the body per unit of time.

    Time frame: Up to approximately 3 years

  8. Characterize Pharmacokinetics(PK) parameter Vd

    volume of distribution

    Time frame: Up to approximately 3 years

  9. Characterize Pharmacokinetics(PK) parameter t1/2

    Half-life time:defined as the time it takes for the concentration of the drug in plasma or serum to be reduced by 50%.

    Time frame: Up to approximately 3 years

  10. Immunogenicity endpoint: Incidence of anti-YL217 antibody (ADAs).

    The presence of ADAs in patients treated with YL217 will be assessed to evaluate immunogenicity.

    Time frame: Up to approximately 3 years

  11. Disease control rate (DCR)

    DCR: defined as the proportion of patients who achieved a best overall response of complete response (CR), partial response (PR) or stable disease (SD).

    Time frame: Up to approximately 3 years

  12. Duration of response (DoR)

    DoR: defined as the time interval from the date of the first documentation of objective response (CR or PR) to the date of the first documentation of progressive disease (PD).

    Time frame: Up to approximately 3 years

  13. Time to response (TTR)

    TTR: defined as the time interval from the date of the first dose of study drug to the date of the first documentation of objective response (CR or PR).

    Time frame: Up to approximately 3 years

  14. Depth of response (DpR)

    DpR: defined as the proportion of target lesion shrinkage from baseline to maximum tumor size.

    Time frame: Up to approximately 3 years

  15. Progression-free survival (PFS)

    PFS: defined as the time interval from the date of the first dose of study drug to the date of first documentation of PD or death due to any cause, whichever occurs first.

    Time frame: Up to approximately 3 years

  16. Overall survival (OS)

    OS: defined as the time interval from the date of the first dose of study drug to the date of death due to any cause.

    Time frame: Up to approximately 3 years

07

Study locations

18 of 21 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2025 (actual). Primary completion is estimated for Jul 2028, 36 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 18, 2025
First posted
Mar 5, 2025
StartActual
Jul 2, 2025
Primary completionEst.
Jul 2028
CompletionEst.
Jul 2030
Last update
Sep 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06859762
Responsible party
Sponsor
First posted
Mar 5, 2025
Start date
Jul 2, 2025
Primary completion
Jul 2028 (estimated)
Completion
Jul 2030 (estimated)
Last update
Sep 18, 2026

Study contacts

Angie Cao, MD
Contact
clinicaltrials@medilinkthera.com
+86 0512-62858368

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion